Gilead announces licence and collaboration deal with Yuhan

Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSD trade secrets suit over clinical trail info thrown out by judge

2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.

Americas

Will Mounjaro and Zepbound get their first US generic rival?

30 June 2026 Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.

Americas

Pfizer’s US Paxlovid patent fight turns on a single error

25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.

More features

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Will Mounjaro and Zepbound get their first US generic rival?

King & Spalding continues hiring spree from pre-merged Winston

Ashurst Perkins Coie opens its doors following landmark merger

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Gilead announces licence and collaboration deal with Yuhan

More on this story

Editor's picks

Editor's picks

More features